Proteasome inhibitors(bortezomib)reverse the adverse effect of abnormal chromosome on multiple myeloma
- VernacularTitle:多发性骨髓瘤细胞遗传学变化及其蛋白酶体抑制剂的疗效观察
- Author:
Li BAO
;
Xiaojun HUANG
;
Xijing LU
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Cytogenetics;
Karyotype;
Prognosis
- From:
Chinese Journal of Practical Internal Medicine
2006;0(20):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study cytogenetic features of multiple myeloma(MM)cells and the relationship between chromosomal karyotypes and subtype,stage,prognostic parameters and treatment of MM.Methods Karyotyping in patients with MM by 24h short-term bone marrow cell culture and G-banding stain were done.Twenty-two patients were treated with conventional chemotherapy(VAD or MP)and 7 patients with Bortezomib(velcade)chemotherapy.Results There was 37.9% of aberrations in patients with multiple myeloma of 29 cases,and the complex and high complex aberrations were 81.8%.Twenty-two patients with VAD or MP chemotherapy;response rate was 81.2% in normal karyotype group;no response was received in the abnormal karyotypes group(P
